Aptose Biosciences Inc (APTO) Stock
APTO is no longer traded. Aptose Biosciences was delisted from the Nasdaq in April 2025.
Prices on this page are historical; the last trade was April 2, 2025 at $2.01.
Aptose Biosciences stock price history
APTO final trading statistics
- Final close
- $2.01
- Final trading day
- Apr 2, 2025
- Market cap at delisting
- $5.13M
- Shares outstanding
- 2.55M
- Final 52-week range
- $0.11 – $3.98
- Avg. volume (final 3 mo.)
- 5,929,806
- All-time high (split-adj.)
- $880875.00 · Mar 2000
- All-time low (split-adj.)
- $1.71 · Apr 2025
- Return since IPO
- -100.0%
- Beta
- 1.13
- Book value / share
- -$14.04
- Price / book
- -0.14
Aptose Biosciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$25.4M | -$36.43 |
| FY2023 | $0.00 | -$51.2M | -$5.62 |
| FY2022 | $0.00 | -$41.8M | -$0.45 |
| FY2021 | $0.00 | -$65.4M | -$0.73 |
| FY2020 | $0.00 | -$55.2M | -$0.67 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Aptose Biosciences stock FAQ
What happened to Aptose Biosciences stock?
Aptose Biosciences stock was delisted from the Nasdaq. Its final close was $2.01 on April 2, 2025.
Is APTO stock still trading?
No. APTO was delisted from the Nasdaq in April 2025 and no longer trades on a U.S. exchange.
What was the last price of APTO stock?
APTO closed at $2.01 on its final trading day, April 2, 2025, for a market value of about $5.13M.
What were Aptose Biosciences's revenue and earnings in its last full fiscal year?
Aptose Biosciences reported revenue of $0.00 and net income of -$25.4M in fiscal 2024, its last full year as a public company.
When did Aptose Biosciences go public?
Aptose Biosciences Inc stock began trading on October 23, 2014.